Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diag...
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
About this item
Full title
Author / Creator
Davies, Christina, Dr , Pan, Hongchao, PhD , Godwin, Jon, DPhil , Gray, Richard, Prof , Arriagada, Rodrigo, Prof , Raina, Vinod, Prof , Abraham, Mirta, MD , Alencar, Victor Hugo Medeiros, MD , Badran, Atef, PhD , Bonfill, Xavier, MD , Bradbury, Joan , Clarke, Michael, Prof , Collins, Rory, Prof , Davis, Susan R, Prof , Delmestri, Antonella, PhD , Forbes, John F, Prof , Haddad, Peiman, Prof , Hou, Ming-Feng, Prof , Inbar, Moshe, Prof , Khaled, Hussein, Prof , Kielanowska, Joanna, MD , Kwan, Wing-Hong, MD , Mathew, Beela S, MD , Mittra, Indraneel, Prof , Müller, Bettina, MD , Nicolucci, Antonio, MD , Peralta, Octavio, MD , Pernas, Fany , Petruzelka, Lubos, Prof , Pienkowski, Tadeusz, Prof , Radhika, Ramachandran, MD , Rajan, Balakrishnan, MD , Rubach, Maryna T, MD , Tort, Sera, MD , Urrútia, Gerard, MD , Valentini, Miriam, MD , Wang, Yaochen, MD , Peto, Richard, Prof , for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group and Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group
Publisher
Kidlington: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years. Methods In the w...
Alternative Titles
Full title
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Authors, Artists and Contributors
Author / Creator
Pan, Hongchao, PhD
Godwin, Jon, DPhil
Gray, Richard, Prof
Arriagada, Rodrigo, Prof
Raina, Vinod, Prof
Abraham, Mirta, MD
Alencar, Victor Hugo Medeiros, MD
Badran, Atef, PhD
Bonfill, Xavier, MD
Bradbury, Joan
Clarke, Michael, Prof
Collins, Rory, Prof
Davis, Susan R, Prof
Delmestri, Antonella, PhD
Forbes, John F, Prof
Haddad, Peiman, Prof
Hou, Ming-Feng, Prof
Inbar, Moshe, Prof
Khaled, Hussein, Prof
Kielanowska, Joanna, MD
Kwan, Wing-Hong, MD
Mathew, Beela S, MD
Mittra, Indraneel, Prof
Müller, Bettina, MD
Nicolucci, Antonio, MD
Peralta, Octavio, MD
Pernas, Fany
Petruzelka, Lubos, Prof
Pienkowski, Tadeusz, Prof
Radhika, Ramachandran, MD
Rajan, Balakrishnan, MD
Rubach, Maryna T, MD
Tort, Sera, MD
Urrútia, Gerard, MD
Valentini, Miriam, MD
Wang, Yaochen, MD
Peto, Richard, Prof
for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_532911
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_532911
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(12)61963-1
